Report: Merck Searching Internally For Next CEO
In May, Merck announced an agreement to acquire the clinical-stage biopharmaceutical company Peloton Therapeutics for $1.05 billion cash upfront and a further $1.15 billion if certain regulatory and sales milestones are reached.
On Wednesday, Merck & Co shares are trading up 0.19% at $84.66.
Photo courtesy of Merck.
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.